AI Terminal
Hansa Biopharma
Declaration of Voting Results & Voting Rights Announcements • Oct 31, 2025
3057_rns_2025-10-31_975704d8-08dc-440e-930e-94c09953030c.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Scheelevägen 22 SE-223 63 Lund, Sweden Phone: +46 46 16 56 70
www.hansabiopharma.com
PRESS RELEASE
Hansa Biopharma: Increase in number of shares and votes
Lund, Sweden October 31, 2025. Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announces that Hansa's registered share capital and number of shares and votes have increased through the issue of 17,000,000 new ordinary shares resolved on October 1, 2025 and registered with the Swedish Companies Registration Office on October 2, 2025, whereby the number of shares and votes increased with 17,000,000 and the share capital increased with SEK 17,000,000.
As of today, the total number of registered shares of Hansa amounts to 101,763,222, of which all are ordinary shares. As of today, the number of votes in Hansa amounts to 101,763,222, and the registered share capital amounts to SEK 101,763,222.
This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on October 31, 2025 at 12:00 PM CET.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer [email protected]
Kerstin Falck, VP Corporate Affairs [email protected]
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.